Interventional Clinical Trial: In this type of study, researchers actively intervene by assigning participants to different groups, administering specific treatments, or manipulating variables. The primary objective is to assess the safety and efficacy of new interventions e.g., drug or medical device.
Key characteristics of interventional clinical trials include:
Randomization: Participants are randomly assigned to different groups, such as the experimental group receiving the intervention and the control group receiving a placebo or standard treatment.
Intervention: Researchers actively administer a specific treatment or intervention to the participants.
Control Group: There is often a control group that receives a placebo or standard treatment for comparison.
Primary Outcomes: Trials are designed to measure predefined primary outcomes, such as improvements in health outcomes, survival rates, or reduction in symptoms.
Regulatory Oversight: Interventional trials require regulatory approval and are usually subject to stricter (risk-proportionate) regulations than non-interventional studies.
Non-interventional Study: These studies focus on collecting data without any active healthcare or treatment intervention imposed by the researchers. Researchers observe and collect information from participants in their natural settings (real world settings) or through retrospective analysis of existing data (secondary use of existing data).
Key characteristics of non-interventional studies include:
Observation: Researchers observe participants and collect data without actively intervening in the healthcare management of the participant or administering any specific treatment (treatment intervention).
Natural Setting: Data is collected in the real-world clinical practice or from existing databases, medical records, surveys, or interviews.
Descriptive Analysis: Non-interventional studies often aim to describe and analyze associations, relationships, patterns, or risk factors in the population under study.
Retrospective or Prospective: Data can be collected retrospectively by analyzing past records or prospectively by following participants over time.
No Randomization: Participants are not randomly assigned to groups, and treatment decisions are made by healthcare providers according to routine clinical practice.
Regulatory Oversight: Every country regulates non-interventional studies differently. The regulatory burden can therefore be much higher than expected.
Both ‘interventional’ clinical trials and non-interventional studies play important roles in advancing medical knowledge. Interventional trials provide more rigorous evidence for evaluating new interventions, while non-interventional studies offer insights into real-world effectiveness, population health, and long-term outcomes.
Share this story...
Real World Evidence (RWE) 101 – Registry vs Registry-Based Study
RWE 101 - Registry vs Registry-Based Study In the context of real-world evidence, a registry is a collection of data on a particular disease, medical condition, or [...]
Real World Evidence (RWE) 101 – Pregnancy Registries
RWE 101 - Pregnancy Registries A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to [...]
Real World Evidence (RWE) 101 – Diversity
RWE 101 - Diversity Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, [...]
Real World Evidence (RWE) 101 – The Patient Voice
RWE 101 - The Patient Voice The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of [...]
Real World Evidence (RWE) 101 – ISPE GPP
RWE 101 - ISPE GPP The International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) provides guidance for the conduct and reporting of pharmacoepidemiologic studies. The key [...]
Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)
RWE 101 - EMA Good Pharmacovigilance Practices (GVPs) The European Medicines Agency's (EMA) Good Pharmacovigilance Practices (GVPs) provide a framework for the monitoring and reporting of adverse drug [...]







